These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7995992)

  • 1. Development of a live, oral, attenuated vaccine against El Tor cholera.
    Taylor DN; Killeen KP; Hack DC; Kenner JR; Coster TS; Beattie DT; Ezzell J; Hyman T; Trofa A; Sjogren MH
    J Infect Dis; 1994 Dec; 170(6):1518-23. PubMed ID: 7995992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
    Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
    Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
    Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
    Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
    J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.
    Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
    J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
    Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
    Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.
    Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF
    Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous antigen expression in Vibrio cholerae vector strains.
    Butterton JR; Beattie DT; Gardel CL; Carroll PA; Hyman T; Killeen KP; Mekalanos JJ; Calderwood SB
    Infect Immun; 1995 Jul; 63(7):2689-96. PubMed ID: 7790086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
    Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
    Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains.
    Benítez JA; Silva AJ; Rodríguez BL; Fando R; Campos J; Robert A; García H; García L; Pérez JL; Oliva R; Torres CA; Ledón T
    Arch Med Res; 1996; 27(3):275-83. PubMed ID: 8854382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
    Chowdhury MI; Sheikh A; Qadri F
    Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.